Novartis received breakthrough designation for Lu-PSMA yesterday. This might speed things up a bit in regards to a LUPIN-2.
https://www.novartis.com/news/novartis-receives-fda-breakthrough-therapy-designation-investigational-177lu-psma-617-patients-metastatic-castration-resistant-prostate-cancer-mcrpc
Ann: Noxopharm Set to Benefit From Novartis ASCO Data, page-11
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
-0.005(4.55%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 10.5¢ | $16.94K | 149.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 15972 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 25454 | 1 |
View Market Depth
| Last trade - 10.59am 26/08/2024 (20 minute delay) ? |
| NOX (ASX) Chart |